Nov 8 (Reuters) - Oncolytics Biotech Inc:
* Oncolytics Biotech Inc. announces 2017 third quarter results
* At September 30, 2017, company reported $14.0 million in cash and cash equivalents; cash runway expected to end of 2018
* Oncolytics Biotech Inc qtrly basic and diluted loss per common share $0.02 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.